Evidence map›Paper›PMID 41624406›Full record

ArticleMolecular therapy. Oncology2026

Survivin/BIRC5-derived peptide disrupts survivin dimerization and cell division and induces multifaceted anti-cancer effects.

Manikandan Santhanam, Venkatadri Babu, Anna Shteinfer-Kuzmine, Swaroop Kumar Pandey, Larisa Gheber, Gilead Raday, Varda Shoshan-Barmatz

Erratum issuedAbstract read
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Manikandan SanthanamDepartment of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Venkatadri BabuDepartment of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Anna Shteinfer-KuzmineThe National Institute for Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Swaroop Kumar PandeyDepartment of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Larisa GheberDepartment of Chemistry, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Gilead RadayRAD Therapeutics Inc, Westlake Village, CA, USA.
Varda Shoshan-BarmatzDepartment of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Survivin, a homodimeric protein overexpressed in virtually all cancers, is largely absent in non-proliferating adult tissues. It is a multifunctional regulator of cellular homeostasis that plays critical roles in proliferation, apoptosis, and immune regulation, which are central to cancer development and progression. Using a peptide array composed of sequences from SMAC/Diablo-interacting proteins, we identified a SMAC-binding sequence within survivin. Here, we report the characterization of a 24-amino-acid peptide spanning key survivin domains: the homodimer interface, microtubule, nuclear import, and chromosomal passenger complex binding sites. The peptide binds survivin and interferes with its dimerization, disrupting interactions with itself and partner proteins such as tubulin. When engineered as stabilized cell-penetrating peptides targeted to the cytosol, mitochondria, or nucleus, they effectively inhibited proliferation, disrupted the completion of mitosis, and induced apoptosis. In lung tumor models, the peptides reduced tumor cell proliferation and growth, while activating anti-tumor immune responses. They increased CD8

Indexed as

apoptosisBIRC5/survivincancercell proliferationmitochondriaMT: Regular IssuePD-L1peptidesSMAC/Diablotubulin

Identifiers

PMID41624406
PMCPMC12857549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.